Adicet Bio Inc

Company Profile

• Business description

  Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

• Contact

  131 Dartmouth Street
  3rd Floor
  BostonMA02116
  USA

  T: +1 650 503-9095

  E: [email protected]

  https://www.adicetbio.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  102